These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38044137)

  • 41. Sorafenib in Metastatic Papillary Thyroid Carcinoma with
    Caterino M; Pirozzi M; Facchini S; Zotta A; Sica A; Lo Giudice G; Rauso R; Varriale E; Ciardiello F; Fasano M
    Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Approach to risk stratification for papillary thyroid carcinoma based on molecular profiling: institutional analysis.
    Staubitz JI; Müller C; Heymans A; Merten C; Roos B; Poplawski A; Ludt A; Strobl S; Springer E; Schad A; Roth W; Musholt TJ; Hartmann N
    BJS Open; 2023 May; 7(3):. PubMed ID: 37146205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
    Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
    Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comprehensive genomic profiling from C-CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1.
    Saito Y; Kage H; Kobayashi K; Kamogashira T; Fukuoka O; Yamamura K; Yamashita S; Tanabe M; Oda K; Kondo K
    Clin Endocrinol (Oxf); 2024 Aug; 101(2):170-179. PubMed ID: 38853441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
    Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF
    Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinical aspect of NTRK-fusions in pediatric papillary thyroid cancer.
    Ricarte-Filho JC; Halada S; O'Neill A; Casado-Medrano V; Laetsch TW; Franco AT; Bauer AJ
    Cancer Genet; 2022 Apr; 262-263():57-63. PubMed ID: 35092884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
    Stanojevic B; Dzodic R; Saenko V; Milovanovic Z; Pupic G; Zivkovic O; Markovic I; Djurisic I; Buta M; Dimitrijevic B; Rogounovitch T; Mitsutake N; Mine M; Shibata Y; Nakashima M; Yamashita S
    Endocr J; 2011; 58(5):381-93. PubMed ID: 21498916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.
    Newfield RS; Jiang W; Sugganth DX; Hantash FM; Lee E; Newbury RO
    Int J Pediatr Otorhinolaryngol; 2022 Jun; 157():111121. PubMed ID: 35397361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome.
    Wong KS; Dong F; Telatar M; Lorch JH; Alexander EK; Marqusee E; Cho NL; Nehs MA; Doherty GM; Afkhami M; Barletta JA
    Thyroid; 2021 Jun; 31(6):933-940. PubMed ID: 33143568
    [No Abstract]   [Full Text] [Related]  

  • 50. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.
    Sun J; Zhang J; Lu J; Gao J; Ren X; Teng L; Duan H; Lin Y; Li X; Zhang B; Liang Z
    PLoS One; 2016; 11(4):e0153319. PubMed ID: 27064992
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Lee DY; Won JK; Lee SH; Park DJ; Jung KC; Sung MW; Wu HG; Kim KH; Park YJ; Hah JH
    Thyroid; 2016 Mar; 26(3):404-13. PubMed ID: 26541309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequent BRAF
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
    Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
    Kunstman JW; Juhlin CC; Goh G; Brown TC; Stenman A; Healy JM; Rubinstein JC; Choi M; Kiss N; Nelson-Williams C; Mane S; Rimm DL; Prasad ML; Höög A; Zedenius J; Larsson C; Korah R; Lifton RP; Carling T
    Hum Mol Genet; 2015 Apr; 24(8):2318-29. PubMed ID: 25576899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon.
    Xu B; Scognamiglio T; Cohen PR; Prasad ML; Hasanovic A; Tuttle RM; Katabi N; Ghossein RA
    Hum Pathol; 2017 Jul; 65():133-139. PubMed ID: 28552827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population.
    Li M; Jia H; Qian Q; Wen P; Chen C; Hua Y; Wang K; Zhang W; Shi F
    Diagn Pathol; 2020 May; 15(1):49. PubMed ID: 32393293
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
    Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G
    Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acquired Secondary RAS Mutation in BRAF
    Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
    Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
    [No Abstract]   [Full Text] [Related]  

  • 58. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
    Liu X; Bishop J; Shan Y; Pai S; Liu D; Murugan AK; Sun H; El-Naggar AK; Xing M
    Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Genetic Duet of
    Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
    J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.